Clinical microbiology and infectious diseases - 11th European Congress. 1-4 April 2001, Istanbul, Turkey
Abstract
This report covers the four different sessions of the congress. All sessions included the presentation of papers about treatment of respiratory tract infections (RTIs). RTIs account for 25% of all the community-acquired infections and are the second most frequent among nosocomial infections after urinary tract infections. Recent years have witnessed a great increase in resistance to antibiotics among pathogens causing RTIs. These changes have rendered several 'classical' antibiotics less effective in this indication. The drug industry has collectively made a great effort to develop new antibiotics to overcome this resistance. In the sessions described below, four different antibiotics were reviewed for their efficacy in RTIs. A relatively 'older' group comprising a beta-lactam and beta-lactamase-inhibitor combination was presented for use both in community and hospital settings. Two different quinolone antibiotics, levofloxacin (Daiichi Seiyaku) and moxifloxacin (Bayer), were the focus of another two sessions. In an era of penicillin resistance in Streptococcus pneumoniae and increasing importance of atypical organisms causing RTIs, the new fluoroquinolone derivatives have become critical agents. These new compounds are proving capable not only of eradicating troublesome pathogens, but also achieving this faster than any other drug. Finally, a new class of antibiotics, namely ketolides, was presented as a novel addition to the macrolide-lincosamide-streptogramin group. In…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.